Navigation Links
Using Early Stage Commercialization Activities to Build Long-Term Success for the Bottom Line
Date:12/18/2007

CHAPEL HILL, N.C., Dec. 18 /PRNewswire/ -- Despite all the scientific advancements in drug discovery and development, it's still a long and expensive trip from the lab to the marketplace. To make that investment of time and money pay off, best-in-class pharmaceutical companies have learned to inject commercial insights early in the product development process, according to research from Best Practices, LLC.

"It's clear early integration of commercialization activities pays off, be it eliminating an unpromising compound early in the development process or achieving success at product launch," said Chris Bogan, chief executive officer of Best Practices, LLC.

The 113-page study found that organizational form or structure is a critical enabler of early integration of commercial activities. Leading companies build an organizational structure that fosters commercialization excellence through integrated portfolio, project and process management programs across a compound's development cycles, according to the study.

The report, "From Genes to Giants: Best Practices in Early-Stage Commercialization," will help leaders in new product planning and market research learn best practices in early-stage product commercialization. The study contains a wealth of insights gleaned from interviews and benchmark surveys with pharma companies such as Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis, and Pfizer.

To download a complimentary summary of the study, go to http://www3.best-in-class.com/rr892.htm .

Some of the findings to emerge from the study include:

-- Centralize early and late-stage commercialization functions to

cultivate better integration among people, resources, activities and

capital-intensive projects.

-- Employ integrated tools, techniques and tactics for portfolio

management and decision analysis to develop understanding and win

broad-based support for tough decisions.

-- Initiate lifecycle management analyses early in the new-product

development process to fully evaluate the potential for multiple

indications, line extensions and new formulations.

Firms that learn how to manage the people variables necessary to optimize product commercialization will win a competitive advantage in the marketplace, the study said.

Download additional findings in the complimentary report summary at: http://www3.best-in-class.com/rr892.htm or contact our Solution Specialists at (919) 403-0251 or bestpractices@best-in-class.com.

If you would like to speak to us about how our research can benefit your organization, please contact Cameron Tew, Manager of Research and Publishing at Best Practices, LLC at (919) 767-9246 or ctew@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. Adverse housing conditions contribute to diabetes risk
3. Females avoid incest by causing male relatives to leave home
4. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing
7. Using the Internet to Promote Exercise
8. Hazards of using crib bumper pads outweigh their benefits
9. Nosespray vaccine using aloe vera has exciting potential, researcher says
10. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
11. Genetic test announced for suicidal ideation in patients using antidepressant drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: the true-life account of ... profound faith of God’s promise of Heaven for His people. “My Journey Through Heaven” ... with his wife, three children and six grandchildren living and doing for God as ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A ... God. “A Respectful Response To Atheist Manifesto” is the creation of published author ... wife, Nancy, for sixty years. He holds graduate degrees from Kent State University ...
(Date:3/23/2017)... ... March 23, 2017 , ... “More Corruption”: a simple and strong explanation of the ... of the rulers of Heaven was asked by God to write a book about Him. ... me just because I kept my commitment to the Lord God. They have not walked ...
(Date:3/22/2017)... ... ... Death anxiety is unconscious and needs understanding and non-judgmental support in a loving ... book titled “ As Good as Goodbyes Get ” (published by Balboa Press AU), ... experiencing at the bedside of patients who were dying. The book centers about questions ...
(Date:3/22/2017)... ... March 23, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that it had ... currently taking place at the Suntec Singapore International Exhibition & Convention Centre, Singapore. ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... YORK , March 23, 2017 ... sample preparation market is expected to reach USD 7.2 billion ... of 7.1%. Sample preparation is a procedure in which a ... crucial step in most analytical procedures since the methods are ... preparation is one of the most shared procedures in the ...
(Date:3/23/2017)... Denmark , March 23, 2017 Ascendis ... its innovative TransCon technology to address significant unmet medical ... will host a conference call and webcast on Monday, ... the Endocrine Society in Orlando, Florida ... disease pipeline candidates (TransCon Growth Hormone, TransCon PTH and ...
(Date:3/23/2017)... , March 23, 2017  Cornerstone Pharmaceuticals, ... a major milestone today.  Following successful End-of-Phase ... U.S. Food and Drug Administration (FDA), the ... and regulatory path forward to conduct pivotal ... patients with acute myeloid leukemia (AML) and ...
Breaking Medicine Technology: